Skip to search formSkip to main contentSkip to account menu

0.8 ML Filgrastim 0.6 MG/ML Prefilled Syringe [Neupogen]

Known as: FILGRASTIM 480 ug in 0.8 mL SUBCUTANEOUS INJECTION, SOLUTION [NEUPOGEN], Neupogen 480 MCG per 0.8 ML Prefilled Syringe, 0.8 ML Neupogen 0.6 MG/ML Prefilled Syringe 
National Institutes of Health

Related topics

Related topics

9 relations
Acetic AcidFilgrastimNeupogenPolysorbate 80

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract P4-12-07: Cost-minimization of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar ZARXIO® over NEUPOGEN®, NEULASTA®, and NEULASTA/ONPRO®: Breast cancer case study
RATIONALE & OBJECTIVES: Biosimilar filgrastim may offer significant cost advantages over originator filgrastim and pegfilgrastim… 
2017
2017
Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A…
2017
2017
Comparative Cost-Efficiency Analysis of Granulocyte Colony-Stimulating Factors for Use in Chemotherapy Patients in the United States
Abstract Introduction: Granulocyte colony-stimulating factors (G-CSFs), when used to reduce the incidence, severity, and duration… 
2016
2016
Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G‐CSF (Zarzio®)
Peripheral blood progenitor cells (PBPCs) have become the major source of hematopoietic progenitor cells for allogeneic… 
2016
2016
Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR)
PurposeAnthracycline and ifosfamide-based chemotherapy represents a widely used regimen both in early and advanced settings in… 
2015
2015
The evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34 + peripheral hematopoietic stem cell mobilisation…
2014
2014
Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers.
2001
2001
Fallbericht zur Therapie mit Granulozyten stimulierendem Faktor beim diabetischen Fuß
ZusammenfassungDer diabetische Fuß entsteht durch das Zusammenwirken mehrerer pathogenetischer Faktoren: Periphere Neuropathie… 
1997
1997
G-CSF bei Radiochemotherapie
ZusammenfassungHintergrundG-CSF (granulocyte-colony-stimulating-factor) beschleunigt die Teilung, Reifung und Freisetzung von… 
1997
1997
472 Rechallenge chemotherapy (CT) with neupogen® (G-CSF) in relapsed small cell lung cancer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)